Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw

doi:10.12337/zgkqjxjyzz.2025.05.004

Chinese Journal of Stomatological Continuing Education ›› 2025, Vol. 28 ›› Issue (5): 322-330.DOI: 10.12337/zgkqjxjyzz.2025.05.004

Previous Articles Next Articles

Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw

Yiyun Zhang, Feiwu Kang, Xueming Zhang^*

Stomatological Hospital and Dental School of Tongji University, Department of Oral and Maxillofacial Surgery, The Affiliated Stomatology Hospital of Tongji University, Shanghai Engineering Research Center of Tooth Restoration and Regeneration, Shanghai, P.R. China

Online:2025-09-30 Published:2025-09-30
Contact: Xueming Zhang. Tel: (021)66315175. Emai: zhangxm@tongji.edu.cn. Address: No. 399, Yanchangzhong Road, Shanghai 200072, P.R. China.

Abstract

Abstract: Drug-related osteonecrosis of the jaw is a severe oral complication caused by anti-resorptive drugs and anti-angiogenic agents. Current clinical management faces significant challenges, with a considerable proportion of patients often having surgical contraindications. There is an urgent need to explore effective non-surgical treatment strategies to alleviate symptoms, improve quality of life, and develop adjunct therapies to reduce recurrence rates and optimize prognosis. This article systematically reviews the latest advancements in non-surgical treatments for drug-related osteonecrosis of the jaw, focusing on the research status, efficacy evidence, and translational potential of pharmacological therapies (such as teriparatide and pentoxyfilline), physical therapies (including hyperbaric oxygen and ozone), as well as stem cell and exosome-based therapies in addressing these critical clinical issues.

Key words: bisphosphonate-associated osteonecrosis of the jaw, medication-related osteonecrosis of the jaw, teriparatide, pentoxifylline, mesenchymal stem cells

Yiyun Zhang, Feiwu Kang, Xueming Zhang. Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 322-330.

References

[1] 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4):313-325.
[2] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update[J]. J Oral Maxillofac Surg, 2022, 80(5): 920-943.
[3] Anastasilakis AD, Pepe J, Napoli N, et al.Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS[J]. J Clin Endocrinol Metab, 2022, 107(5):1441-1460.
[4] Jiang A, Zhang Z, Qiu X, et al.Medication-related osteonecrosis of the jaw (MRONJ): a review of pathogenesis hypothesis and therapy strategies[J]. Arch Toxicol, 2024, 98(3):689-708.
[5] Yarom N, Shapiro CL, Peterson DE, et al.Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline[J]. J Clin Oncol, 2019, 37(25):2270-2290.
[6] 孙国文, 田美. 药物相关性颌骨坏死不同阶段治疗方法述评[J]. 口腔颌面外科杂志, 2022, 32(3):135-143.
[7] Girotra M, Rubin MR, Bilezikian JP.The use of parathyroid hormone in the treatment of osteoporosis[J]. Rev Endocr Metab Disord, 2006, 7(1-2):113-121.
[8] Beaudart C, Veronese N, Douxfils J, et al.PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis[J]. Osteoporos Int, 2025, 36(6): 951-967.
[9] Guyer L, Lehmann O, Wenger M, et al.Long-term impact of teriparatide on bone mineral density, trabecular bone score, and fracture risk relative to total hip T-score: A two-decade, registry-based cohort study[J]. Bone, 2025, 195:117445.
[10] Harper RP, Fung E.Resolution of bisphosphonate-associated osteonecrosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)][J]. J Oral Maxillofac Surg, 2007, 65(3):573-580.
[11] Ohbayashi Y, Miyake M, Sawai F, et al.Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(4):e31-e37.
[12] Lau AN, Adachi JD.Resolution of osteonecrosis of the jaw after teriparatide [recombinant human PTH-(1-34)] therapy[J]. J Rheumatol, 2009, 36(8):1835-1837.
[13] Lee JJ, Cheng SJ, Jeng JH, et al.Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy[J]. Head Neck, 2011, 33(9):1366-1371.
[14] Singh A, Chung K, Huryn JM, et al.Teriparatide as an adjuvant therapy in the management of advanced-stage medication-related osteonecrosis of the jaw[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2025, 140(3):e59-e63.
[15] Cheung A, Seeman E.Teriparatide therapy for alendronate-associated osteonecrosis of the jaw[J]. N Engl J Med, 2010, 363(25):2473-2474.
[16] Doh RM, Park HJ, Rhee Y, et al.Teriparatide therapy for bisphosphonate-related osteonecrosis of the jaw associated with dental implants[J]. Implant Dent, 2015, 24(2):222-226.
[17] Neuprez A, Rompen E, Crielaard JM, et al.Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient[J]. Calcif Tissue Int, 2014, 95(1):94-96.
[18] Mohamed MM, Gunasekera WM, Glew D, et al.Teriparatide therapy for medication-related osteonecrosis of the jaw: case report and literature review[J]. Clin Med (Lond), 2022, 22(Suppl 4):20-21.
[19] Yoshiga D, Yamashita Y, Nakamichi I, et al.Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws[J]. Osteoporos Int, 2013, 24(8):2365-2369.
[20] Sim IW, Borromeo GL, Tsao C, et al.Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial[J]. J Clin Oncol, 2020, 38(26):2971-2980.
[21] Park JH, Park W, Nguyen LP, et al.Treatment period and changes in bone markers according to the application of teriparatide in treating medication-related osteonecrosis of the jaw[J]. BMC Oral Health, 2025, 25(1):528.
[22] Krege JH, Gilsenan AW, Komacko JL, et al.Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates[J]. JBMR Plus, 2022, 6(9):e10665.
[23] Gilsenan A, Midkiff K, Harris D, et al.Teriparatide Did Not Increase Adult Osteosarcoma Incidence in a 15-Year US Postmarketing Surveillance Study[J]. J Bone Miner Res, 2020, 36(2):244-251.
[24] Khoury W, Trus R, Chen X, et al.Parsimonious Effect of Pentoxifylline on Angiogenesis: A Novel Pentoxifylline-Biased Adenosine G Protein-Coupled Receptor Signaling Platform[J]. Cells, 2023, 12(8):1199.
[25] Owosho AA, Estilo CL, Huryn JM, et al.Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(4):455-459.
[26] Słowik Ł, Totoń E, Nowak A, et al.Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol[J]. J Clin Med, 2025, 14(3):974.
[27] Magalhães JMI, da Motta Silveira FM, Regueira LS, et al. Pentoxifylline and tocopherol as prophylaxis for osteonecrosis of the jaw due to bone-modifying agents in patients with cancer submitted to tooth extraction: a case series[J]. Support Care Cancer, 2023, 31(8):462.
[28] De Morais RPL, De Aguiar AWPB, de Hora Sales PH, et al. Is the use of Pentoxifylline and Tocopherol effective in the treatment of Osteoradionecrosis of the jaws or for the treatment of medication osteonecrosis of the jaw? An overview[J]. J Stomatol Oral Maxillofac Surg, 2024, 125(5 supple 1):101959.
[29] Brunner C, Arvandi M, Marth C, et al.Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study[J]. J Clin Oncol, 2025, 43(2):180-188.
[30] Playdon MC, Ziegler RG, Sampson JN, et al.Nutritional metabolomics and breast cancer risk in a prospective study[J]. Am J Clin Nutr, 2017, 106(2):637-649.
[31] De Oliveira VA, Oliveira IKF, Pereira IC, et al.Consumption and supplementation of vitamin E in breast cancer risk, treatment, and outcomes: A systematic review with meta-analysis[J]. Clin Nutr ESPEN, 2023, 54: 215-226.
[32] Nava-Tapia DA, Román-Justo NY, Cuenca-Rojo A, et al.Exploring the potential of tocopherols: mechanisms of action and perspectives in the prevention and treatment of breast cancer[J]. Med Oncol, 2024, 41(9):208.
[33] Ortega MA, Fraile-Martinez O, García-Montero C, et al.A General Overview on the Hyperbaric Oxygen Therapy: Applications, Mechanisms and Translational Opportunities[J]. Medicina (Kaunas), 2021, 57(9):864.
[34] Silva ML, Tasso L, Azambuja AA, et al.Effect of hyperbaric oxygen therapy on tooth extraction sites in rats subjected to bisphosphonate therapy—histomorphometric and immunohistochemical analysis[J]. Clin Oral Investig, 2017, 21(1):199-210.
[35] Liu SS, Lin TY, Fu E, et al.Immediate hyperbaric oxygen after tooth extraction ameliorates bisphosphonate-related osteonecrotic lesion in rats[J]. J Periodontol, 2019, 90(12): 1449-1456.
[36] Watanabe T, Asai K, Fukuhara S, et al.Effectiveness of surgery and hyperbaric oxygen for antiresorptive agent-related osteonecrosis of the jaw: A subgroup analysis by disease stage[J]. PLoS One, 2021, 16(1):e0244859.
[37] Pereira-Silva M, Hadad H, de Jesus LK, et al. Ozone therapy effect in medication-related osteonecrosis of the jaw as prevention or treatment: microtomographic, confocal laser microscopy and histomorphometric analysis[J]. Clin Oral Investig, 2024, 28(2):151.
[38] Delanora LA, de Lima Neto TJ, da Rocha TE, et al. Systemic Ozone Therapy Improves Oral Hard and Soft Tissue Healing in Medication-Related Osteonecrosis of the Jaw (MRONJ): A Study in Senescent Female Rats[J]. Biomedicines, 2025, 13(5):1248.
[39] Di Fede O, Del Gaizo C, Panzarella V, et al.Ozone Infiltration for Osteonecrosis of the Jaw Therapy: A Case Series[J]. J Clin Med, 2022, 11(18):5307.
[40] Di Fede O, La Mantia G, Del Gaizo C, et al.Reduction of MRONJ risk after exodontia by virtue of ozone infiltration: A randomized clinical trial[J]. Oral Dis, 2024, 30(8):5183-5194.
[41] Berni M, Brancato AM, Torriani C, et al.The Role of Low-Level Laser Therapy in Bone Healing: Systematic Review[J]. Int J Mol Sci, 2023, 24(8):7094.
[42] Ayhan M, Gedik B, Kalelioglu EE, et al.Comparison of the Effects of Four Laser Wavelengths on Medication-Related Osteonecrosis of the Jaw (MRONJ) in a Murine Model: An In Vivo Photobiomodulation Study[J]. Int J Med Sci, 2024, 21(15):2959-2973.
[43] Tenore G, Mohsen A, Del Vecchio A, et al.Surgical extraction with photobiomodulation as an adjunctive modality in patients at-risk for medication-related osteonecrosis of the jaw: retrospective study[J]. BMC Oral Health, 2025, 25(1):627.
[44] Park JH, Cho S, Kim SJ, et al.Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study[J]. Osteoporos Int, 2022, 33(2):367-377.
[45] Lorenzo-Pouso AI, Bravo SB, Carballo J, et al.Quantitative proteomics in medication-related osteonecrosis of the jaw: A proof-of-concept study[J]. Oral Dis, 2023, 29(5):2117-2129.
[46] Yang G, Singh S, McDonough CW, et al. Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw[J]. Clin Pharmacol Ther, 2021, 110(6):1558-1569.
[47] Lin H, Sohn J, Shen H, et al.Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing[J]. Biomaterials, 2019, 203:96-110.
[48] Tian RC, Zhang RY, Ma CF.Rejuvenation of Bone Marrow Mesenchymal Stem Cells: Mechanisms and Their Application in Senile Osteoporosis Treatment[J]. Biomolecules, 2025, 15(2):276.
[49] Voss PJ, Matsumoto A, Alvarado E, et al.Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells[J]. Odontology, 2017, 105(4): 484-493.
[50] 黄李蓉, 冯泽儒, 吴红崑, 等. 富血小板纤维蛋白促进骨再生效果的研究[J].中国口腔种植学杂志, 2025, 30(2):118-126.
[51] Dohan Ehrenfest DM, Rasmusson L, Albrektsson T.Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte-and platelet-rich fibrin (L-PRF)[J]. Trends Biotechnol, 2009, 27(3):158-167.
[52] Bouland C, Meuleman N, Widelec J, et al.Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF[J]. J Stomatol Oral Maxillofac Surg, 2021, 122(2):212-218.
[53] Zheng Y, Dong X, Wang X, et al.Exosomes Derived from Adipose Tissue-Derived Mesenchymal Stromal Cells Prevent Medication-Related Osteonecrosis of the Jaw through IL-1RA[J]. Int J Mol Sci, 2023, 24(10):8694.
[54] Zheng Y, Wang X, He Y, et al.Exosomes from Adipose-Derived Mesenchymal Stromal Cells Prevent Medication-Related Osteonecrosis of the Jaw by Inhibiting Macrophage M1 Polarization and Pyroptosis[J]. Int J Nanomedicine, 2024, 19:12675-12693.
[55] Dong X, Shen LH, Yi Z, et al.Exosomes from Adipose-Derived Stem Cells Can Prevent Medication-Related Osteonecrosis of the Jaw[J]. Med Sci Monit, 2021, 27: e929684.
[56] Ogata K, Katagiri W, Hibi H.Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro[J]. Clin Oral Investig, 2017, 21(6):1979-1988.

Research Advances in Non-Surgical Management of Medication-Related Osteonecrosis of the Jaw

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 7

Recommended Articles

Metrics

Comments

[1]	Yihui Ding, Dandan Wang, Chenlu Li, Jihong Wang, Lei Tian, Chunlin Zong. Effect of Teriparatide on Therapy of Medication-related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 297-306.
[2]	Jinyuan He, Guowen Sun. Research Progress on the Mechanism and Treatment of Medication-related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 307-311.
[3]	Bingyue Xu, Han Lu, Keying Liu, Wei He. Advances in the Study of Microecological Dysbiosis in Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 312-321.
[4]	Chenxi Jiang, Guowen Sun. Research Progress in Clinical Diagnosis and Treatment of Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 331-336.
[5]	Rui Wang, Guowen Sun. A Retrospective Study of Surgical Treatment of Stage 3 Medication-Related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 345-352.
[6]	Jinyuan He, Guowen Sun. One Case of the Guide Plate to Improve the Occlusal Relationship of Mandibular Medication-related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 360-366.
[7]	Na Li, Yuan Chang, Ning Gao, Kun Fu, Jinghua Cai, Zhenjie GAO, Xianghe Qiao, Leilei Yang, Wei He. Clinical Application of “Internet+”Case Teaching Method in Medication-related Osteonecrosis of the Jaw [J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 367-374.